The rise of copyright’s blockbuster initially sparked a boom for pharma, nevertheless recent changes present a murky scenario for shareholders. Lower-cost alternatives are eroding profits, and ongoing litigation add https://louisetisw656583.acidblog.net/72434436/the-blue-pill-and-pharma-a-risky-bet